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Abstract:
Background:
The Global Burden of Disease 2010 study reported the relative size of major depressive disorder (MDD) burden to be greater in the
Middle  East  and  North  Africa  than  anywhere  else.  However,  little  research  has  been  carried  out  to  examine  the  comparative
effectiveness of antidepressants in this region.
Objective:
To assess and compare functioning levels in Middle Eastern patients with MDD treated with either duloxetine or a selective serotonin
reuptake inhibitor (SSRI), and to examine the impacts of depression-related pain on functioning by the type of treatment.
Method:
This post-hoc analysis, which focused on Middle Eastern patients, used data from a 6-month prospective observational study that
included 1,549 MDD patients without sexual dysfunction. Levels of functional impairment and depression-related pain were assessed
using the Sheehan Disability Scale (SDS) and the modified Somatic Symptom Inventory, respectively. A mixed model with repeated
measures (MMRM) was employed.
Results:
The mean age of the patients was 37.3 (SD=8.4) years, and 34.6% were female. Patient functioning was, on average, moderately
impaired at baseline, but improved substantially during follow-up in both the duloxetine (n=152) and the SSRI (n=123) cohorts. The
MMRM  results  showed  a  lower  level  of  functional  impairment  at  24  weeks  in  the  duloxetine  cohort  than  in  the  SSRI  cohort
(p<0.001). Pain severity at baseline was positively associated with functional impairment during follow-up only in the SSRI cohort
(p=0.003).
Conclusion:
Duloxetine-treated MDD patients achieved better functioning than SSRI-treated patients. This treatment difference was partly driven
by depression-related pain.
* Address correspondence to this author at the Department of Healthcare Management, College of Social Science, Gachon University, Seongnam-si,
South Korea, 13120; Tel: +82 31 750 5205; E-mail: jihyung.hong.kr@gmail.com
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1. INTRODUCTION
Depression is one of the most prevalent, disabling and costly mental illnesses, currently affecting over 300 million
people worldwide [1]. According to the World Mental Health (WHM) survey conducted in 18 countries, the life-time
prevalence of major depressive episode (MDE) was found to be up to 21%. The survey also revealed a great variation in
the prevalence of MDE across different countries – it tended to be higher in some Western countries but lower in Asian
and Middle Eastern countries. For instance, it was found to be 19.2% in the United States and 21.0% in France but 6.5%
in China, 6.6% in Japan and 10.9% in Lebanon - the only Arab country included in the survey [2]. However, these
estimates are based on data from 2001-2007, and emerging evidence suggests that the prevalence of depression in these
latter countries is probably higher than what is reported in the survey. For example, the 2010 Global Burden of Disease
(GBD) study reported the relative size of major depressive disorder (MDD) burden, measured in disability adjusted life
years (DALYs), to be greater in the Middle East and North Africa (MENA) than anywhere else, particularly in women
in this region [3, 4]. Unfortunately, this high level of MDD burden is expected to continue because wars and conflicts in
the MENA region are likely to further increase the prevalence and the burden of MDD [5].
The high level of DALYs due to depression, which accounts for nearly half (40.5%) of the total DALYs associated
with mental and substance use disorders [6], translates into a substantial economic burden of the disease. Although such
estimates are not available in the MENA region, the total costs of depression were estimated to be about ¥2 trillion
(about US$20 billion) in Japan (2005 value) [7], over US$6 billion in China (2002 value) [8], and over US$4 billion in
South Korea (2005 value) [9]. Notably, indirect costs associated with lost productivity far exceeded direct medical costs
of depression in all studies. This implies that patients with depression have substantial impairment in functioning and
health-related quality of life (HRQoL).
Indeed, nearly two-thirds of MDD patients were reported to have severe impairment in functioning and HRQoL,
respectively [10, 11]. Such impairment may be even more pronounced in countries, for instance those of the MENA
region, where access to mental health care is severely limited due to the strong stigma attached to mental illness [12].
Furthermore, a high proportion of psychiatric patients also tend to somatise their emotional problems and communicate
them in the form of physical symptoms in such cultures [13]. Many of them seek help first from primary care physicians
and present to them with physical complaints such as headache, heart/chest pain, back pain, and abdominal pain, rather
than  psychological  complaints.  These  physical  symptoms,  either  as  a  manifestation  of  MDD  or  as  a  coexisting
condition, not only delay the diagnosis and treatment of MDD but also further interfere with daily functioning and
HRQoL in patients with MDD [14, 15].
Duloxetine hydrochloride is a potent and relatively balanced inhibitor of serotonin and norepinephrine reuptake
(SNRI) [16]. It has been approved not only for the management of MDD and generalised anxiety disorder but also for
pain-related conditions (chronic musculoskeletal pain, fibromyalgia, and diabetic peripheral neuropathic pain) in the
United States. It has also been approved for some or all of them in many other countries, including the countries of the
MENA region. Limited evidence, mostly from the United States and Europe, suggests that the dual action of SNRIs
may more effectively control the symptoms of depression than those antidepressants inhibiting only one monoamine at
least for the subgroup of MDD patients with concomitant pain [17 - 19]. This is because the pathophysiology of both
conditions likely involve an imbalance of serotonin and norepinephrine [20]. More research is needed to establish this
hypothesis, especially in the MENA region, where the effects of such agents have never been evaluated [21].
This post-hoc study aimed to assess and compare the level of functional impairment over time in MDD patients
treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) for up to 6 months in actual clinical
settings  in  Saudi  Arabia  and  the  United  Arab  Emirates  (UAE),  using  data  from  an  international  prospective
observational study. This study also examined whether the impacts of depression-related pain on functioning varied
with the type of treatment.
2. MATERIAL AND METHODS
2.1. Study Design
This study used data from a 6-month, multi-national, prospective, non-interventional, observational study. It was
primarily designed to examine treatment-emergent sexual dysfunction (TESD) and other treatment outcomes among
patients with MDD who were treated with either an SNRI or a selective serotonin reuptake inhibitor (SSRI) in actual
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clinical practice. A total of 1,549 patients, out of 1,647 patients who were enrolled between Nov 2007 and Nov 2008,
were classified as “sexually active patients without sexual dysfunction at study entry”. This post-hoc study focused only
on those patients from the Middle East (n=314) (Saudi Arabia [n=179] and United Arab Emirates (UAE) [n=135]).
This study followed the ethical standards of responsible local committees and the regulations of the participating
countries. Ethical review board (ERB) approval was obtained as required by local laws. All patients provided informed
consent  for  the  provision  and  collection  of  the  data.  This  study  was  also  conducted  in  accordance  with  the  ethical
principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemology
Practices  (GPPs),  as  well  as  applicable  laws  and  regulations  of  the  countries  where  the  study  was  conducted,  as
appropriate.
Further details of the study design have been published elsewhere [22 - 26].
2.2. Study Sample
Patients were eligible to participate in the study if they met the following inclusion criteria: (1) at least 18 years of
age;  (2)  presenting  with  an  episode  of  MDD  in  an  outpatient  setting,  with  MDD  diagnosed  according  to  the
International Statistical Classification of Diseases 10th revision (ICD-10) [27]or Diagnostic and Statistical Manual of
Mental  Disorders-4th  edition  text  revision  (DSM-IV-TR)  [28]  criteria;  (3)  the  Clinical  Global  Impression-Severity
(CGI-S)  score  of  ≥4  (i.e.,  at  least  moderately  ill)  [29];  (4)  initiating  or  switching  to  any  available  SSRI  or  SNRI
antidepressant  in  accordance  with  a  treating  psychiatrist’s  discretion;  (5)  being  sexually  active  without  sexual
dysfunction, as defined by Arizona Sexual Experience Scale (ASEX) [30]; and (6) providing consent to release data.
The  study  excluded  patients  who  (1)  were  participating  in  another  study;  (2)  had  a  history  of  treatment-resistant
depression; (3) had a past or current diagnosis of schizophrenia, schizophreniform or schizoaffective disorder, bipolar
disorder, dysthymia, mental retardation or dementia; or (4) received any antidepressant within 1 week (1 month for
fluoxetine)  prior  to  study  entry,  with  the  exception  of  patients  receiving  an  ineffective  treatment  for  whom  the
immediate switch to an SSRI or an SNRI antidepressant was considered to be the best treatment option.
Patients were, however, not required to continue their initial medications. Changes in medication and dosing were
possible at any time during follow-up, as determined by their treating psychiatrist.
2.3. Data Collection and Outcome Assessment
Data were collected during visits within the normal course of care. Subsequent data collection was targeted at week
8, week 16, and week 24 from the baseline visit (i.e., study entry). Patient socio-demographics and clinical history were
recorded at the baseline assessment. Clinical severity of depression was assessed at each visit using the CGI-S [29] and
the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16) [31].
Functional impairment was also assessed at each visit using the Sheehan Disability Scale (SDS) [32]. It is a brief
self-report  inventory  that  assesses  functional  impairment  in  work/school,  social  life,  and  family  life.  The  level  of
functional impairment in each of the three domains is rated from 0 to 10. The level of global functional impairment is
determined with the sum of the three subscores. A higher score indicates a higher level of functional impairment.
Depression-related pain severity was measured using the pain-related items of  the Somatic Symptom Inventory
(SSI), which includes headaches, heart/chest pain, neck pain, abdominal pain, lower back pain, joint pain, and muscular
soreness [33]. PPS status was also assessed as painful physical symptom negative (PPS-) or positive (PPS+); PPS+ was
defined as a mean score of at least 2 for the seven pain-related items of the SSI.
2.4. Statistical Analysis
This post-hoc study included 275 patients, out of the 314 patients from Saudi Arabia and UAE, who (1) initiated
either duloxetine or an SSRI as monotherapy at baseline, and (2) who had non-missing data on the QIDS-SR16 score at
baseline with at least one non-missing QIDS-SR16 score during follow-up (n=152 in the duloxetine cohort and n=123 in
the SSRI cohort).  This study analysed the patient  observations up to the point  where their  initial  medications were
discontinued (n=127 [83.6%] in the duloxetine cohort and n=97 [78.9%] in the SSRI cohort available at 24 weeks).
The  baseline  socio-demographic  and clinical  characteristics  of  the  two treatment  cohorts  were  summarised  and
compared using the Chi-square test (for categorical variables) and the Mann-Whitney test (for continuous variables).
The level of functional impairment (both SDS total scores and SDS subscores) at each visit was also described and
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compared  using  the  Mann-Whitney  test.  The  treatment  difference  in  functional  impairment  at  each  visit  was  also
expressed in terms of the effect size, using Cohen’s d [34].
The mixed effects models for repeated measures (MMRM) analysis was used to estimate and compare the levels of
functional impairment (SDS total, work, social life, and family life) during follow-up between the two treatment groups.
The models were adjusted for age, gender, SSI-pain score at baseline, QIDS-SR16 score at baseline, the baseline value of
the outcome modelled, and visit number. The models were further adjusted for the following variables if they appeared
to be significant (p<0.1) when each one of them was added to the above model: independent living (living in his/her
own house), living with a spouse/partner, employment status, having MDD episodes in the 24 months prior to study
entry,  MDD hospitalisations  in  the  24  months  prior  to  study  entry,  and  the  number  of  any  significant  pre-existing
comorbidities. Finally, the models also included the interaction term between time (visit number) and treatment if it
appeared to be significant (p<0.05) in the full model.
All analyses were repeated for each subgroup of patients treated with duloxetine and SSRIs to examine whether the
association between depression-related pain (SSI-pain score) and functional impairment (SDS total score) was mediated
or moderated by the type of treatment. In addition, the MMRM analysis was further conducted to compare the impacts
of  duloxetine  and  SSRIs  on  depression-related  pain  during  follow-up.  The  same  list  of  independent  variables
aforementioned  were  considered  in  the  model.
All statistical analyses were performed using SAS version 9.3 for Windows (SAS Institute, Cary, NC, USA).
3. RESULTS
3.1. The Characteristics of Patients at Baseline
A total of 275 patients were included in the final analysis. Overall, the mean (standard deviation [SD]) age of these
patients was 37.3 (SD=8.4) years, and only about one-third of them (34.6%) were female (27.1% in Saudi Arabia and
44.2% in the UAE, p=0.003). Slightly more than half of the patients (56.4%) were from Saudi Arabia, and the rest were
from the UAE (43.6%). The majority of the patients (76.7%) were living with a spouse. About two-thirds of the patients
(67.3%) had full-time employment, and more than half of the patients (57.8%) completed at least a tertiary or university
degree. In addition, nearly two-thirds of these MDD patients (61.5%) also suffered from PPS at baseline. Only 20% of
MDD patients had taken antidepressants, and 48.4% (21.1% for benzodiazepines and the 27.3% for other medications)
had taken other psychiatric medications in the previous 24 months.
Of the 275 patients, 152 initiated duloxetine at baseline and the rest (n=123) initiated an SSRI antidepressant at
baseline. The most common SSRIs prescribed at baseline were escitalopram (38.2%), paroxetine (27.6%), and sertraline
(20.3%). The median daily doses (interquartile ranges [IQRs]) of these antidepressants at baseline were 10.0mg/d (IQR:
10.0mg/d  –  10.0mg/d)  for  escitalopram,  22.5mg/d  (IQR:  20.0mg/d  –  25.0mg/d)  for  paroxetine,  50.0mg/d  (IQR:
50.0mg/d – 100.0mg/d) for sertraline, and 60.0mg/d (60.0mg/d – 60.0mg/d) for duloxetine.
Table (1) summarises the baseline patient characteristics by treatment cohorts. A higher proportion of the SSRI
cohort were female (p=0.015) and from the UAE (p=0.003), whereas a higher proportion of the duloxetine cohort had
completed a tertiary or university degree (p=0.013). In addition, a higher proportion of the SSRI cohort had taken other
psychiatric medications in the previous 24 months (37.4% vs. 19.1%), whereas a higher proportion of the duloxetine
cohort had taken benzodiazepines in the previous 24 months (26.3% vs. 14.6%) (p=0.001). Nevertheless, the levels of
depression  severity  and  depression-related  pain  at  baseline  were  similar  for  the  two cohorts,  and  the  proportion  of
patients exhibiting PPS at baseline was also similar for the two (63.8% in the duloxetine cohort and 58.5% in the SSRI
cohort, p=0.371).
Table 1. Baseline patient characteristics, by treatment cohorts.
Baseline Characteristic Duloxetine(n=152) SSRI (n=123) P-value
Age, Mean (SD) 36.9 (7.9) 37.7 (9.1) 0.673
Female, % 28.3 42.3 0.015
Caucasian, % 83.6 86.2 0.547
United Arab Emirates, % 35.5 53.7 0.003
Age at First Symptoms of MDD, Mean (SD) 31.5 (7.3) 31.3 (8.6) 0.787
BMI (kg/m
2
), Mean (SD) 26.9 (4.2) 26.5 (4.1) 0.582
Living with a Spouse, % 77.0 76.4 0.838
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Baseline Characteristic Duloxetine(n=152) SSRI (n=123) P-value
Independent Living, % 13.8 15.4 0.703
Level of Education, % - - 0.013
University or More 63.8 50.4 -
Secondary School/Occupational Programme 32.2 37.4 -
Primary School or Less 3.9 12.2 -
CGI-S, Mean (SD) 4.5 (0.6) 4.5 (0.6) 0.310
QIDS-SR16, Mean (SD) 12.6 (4.5) 12.0 (4.9) 0.234
SSI-pain, Mean (SD) 15.7 (4.9) 14.7 (4.9) 0.098
Painful Physical Symptoms, % 63.8 58.5 0.371
Number of Comorbidities, % - - 0.050
None 87.4 76.0 -
1 11.3 21.5 -
≥ 2 1.3 2.5 -
Had MDD Episodes in the Past 24 Months, % 78.9 82.1 0.511
Had been Hospitalised for MDD in the Past 24 Months, % 2.6 6.5 0.118
Had Taken Antidepressants in the Past 24 Months, % 21.1 18.7 0.885
Had Taken other Psychiatric Medications in the Past 24 Months, % - - 0.001
Benzodiazepines 26.3 14.6 -
Other 19.1 37.4 -
None 54.6 48.0 -
Abbreviations: BMI, Body Mass Index; CGI-S, Clinical Global Impressions of Severity; MDD, Major Depressive Disorder; QIDS-SR16, 16-item
Quick Inventory of Depressive Symptomatology Self-Report; SD, Standard Deviation; SSI, Somatic Symptom Inventory; SSRI, Selective Serotonin
Reuptake Inhibitor
3.2. The Level of Functional Impairment over Time by Treatment Cohort
Table  (2)  demonstrates  the  mean  levels  of  functional  impairment  at  baseline  and  at  24  weeks,  respectively,  by
treatment cohort. At baseline, the level of functional impairment was slightly higher in the duloxetine cohort than in the
SSRI cohort: the mean SDS total score at baseline was 17.36 (SD=6.00) in the former and 15.66 (SD=6.28) in the latter
(p=0.012). Nevertheless, both treatment groups, on average, had a moderate level of functional impairment in all three
subdomains (SDS work, social life, and family life), with a mean score of 5.35 (SD=2.66) (for work) to 6.24 (SD=2.16)
(for social life) in the duloxetine cohort and 5.11 (SD=2.41) (for work) to 5.35 (SD=2.17) (for social life) in the SSRI
cohort.
Table 2. Mean levels (raw values) of SDS total and subscores at baseline and at 24 weeks, by treatment cohorts.
Outcome Duloxetine SSRI P-value Effect sizea
At Baseline
SDS Total Score 17.36 (6.00) 15.66 (6.28) 0.012 0.28
SDS Work Score 5.35 (2.66) 5.11 (2.41) 0.186 0.09
SDS Social Life Score 6.24 (2.16) 5.35 (2.17) <0.001 0.41
SDS Family Life Score 5.77 (2.29) 5.20 (2.19) 0.019 0.25
At 24 weeks
SDS Total Score 3.41 (3.06) 4.60 (3.21) 0.008 -0.38
SDS Work Score 1.09 (1.23) 1.67 (1.27) 0.001 -0.47
SDS Social Life Score 1.24 (1.04) 1.51 (1.11) 0.087 -0.25
SDS Family Life Score 1.08 (1.01) 1.41 (1.04) 0.024 -0.32
a These show effect sizes of differences in functional impairment between treatment cohorts. Abbreviations: SDS, Sheehan Disability Scale; SSRI,
Selective Serotonin Reuptake Inhibitor
Despite  a  higher  level  of  baseline  functional  impairment,  the  duloxetine  cohort  achieved  a  greater  level  of
functioning at 24 weeks, compared to the SSRI cohort. At 24 weeks, the mean SDS total score was 3.41 (SD=3.06) in
the former and 4.60 (SD=3.21) in the latter (p=0.008). Similar patterns were also observed in all three SDS subdomains.
This treatment difference was equivalent to the effect size of -0.38 for SDS total (subdomains: -0.25 for SDS social life
to -0.47 for SDS work).
The level of functional impairment at 24 weeks was still lower in the duloxetine cohort than in the SSRI cohort even
(Table 1) contd.....
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when the adjustment of baseline differences was made through the MMRM, as shown in Table (3) and Fig. (1). At 24
weeks, the estimated mean SDS total score (i.e., least squares [LS] means) was 3.13 (standard error [SE]=0.26) in the
former, which was lower than that of 4.96 (SE=0.29) in the latter (p<0.001) (i.e. better functioning in the duloxetine
cohort) (Fig. 1).




Intercept 9.35 1.67 <0.001
Age -0.02 0.02 0.338
Female (vs. male) -0.31 0.39 0.421
CGI -0.18 0.39 0.642
QIDS-SR16 Score at Baseline -0.31 0.06 <0.001
SSI-Pain Score at Baseline 0.10 0.05 0.030
SDS Total Score at Baseline 0.31 0.03 <0.001
Duloxetine (vs. SSRI)a -0.25 0.64 0.697
Weeks (vs. Week 8)a
Week 16 -4.41 0.44 <0.001
Week 24 -5.49 0.48 <0.001
Weeks*Treatmenta
Duloxetine at Week 16 -0.58 0.58 0.324
Duloxetine at Week 24 -1.58 0.65 0.015
a As the model included the interaction term between treatment and time (weeks), the interpretation of the coefficients of treatment and time is not
straightforward. The least squares mean of the SDS total score at each post-baseline visit by treatment cohorts was further estimated and presented in
(Fig. 1). Abbreviations: QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology Self-Report; SDS, Sheehan Disability Scale; SSI,
Somatic Symptom Inventory; SSRI, Selective Serotonin Reuptake Inhibitor
Fig. (1). The estimated SDS total scores during follow-up, by treatment cohorts.
Notably,  the  level  of  depression-related pain  at  baseline,  as  measured by SSI-pain  scores,  was  also  statistically
significantly  associated with  the level  of  functional  impairment  during follow-up (coefficient=0.10,  p=0.030).  This
positive  association  between  the  two  was  even  more  apparent  in  the  subgroup  of  SSRI-treated  patients
(coefficient=0.23, p=0.003), but not in the subgroup of duloxetine-treated patients (coefficient=0.04, p=0.500) (Fig. 2).
In relation to this finding, an additional analysis was conducted to confirm the differential impacts of duloxetine and
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statistically significantly lower in duloxetine-treated patients (LS means [SE]: 8.31 [0.24]) than in SSRI-treated patients
(LS means [SE]: 11.14 [0.28]) (p<0.001) (data not shown).
Fig. (2). The results of MMRM analyses: associations between baseline SSI-pain scores and SDS total scores during follow-up, by
treatment cohorts.
4. DISCUSSION
This post-hoc analysis assessed the level of functional impairment over time, using the Sheehan Disability Scale
[32], in the subgroup of Middle Eastern patients with MDD, who were either treated with duloxetine or with an SSRI
for up to 6 months in actual clinical practice in Saudi Arabia and the UAE. The results showed that this subgroup of
patients had a moderate level of functional impairment in all three SDS subdomains (work, social life, and family life)
at baseline, but the patients, particularly those patients treated with duloxetine, achieved better functioning over time in
all three subdomains. The findings also highlighted the differential impacts of depression-related pain on functioning by
treatment  cohorts.  The  negative  impact  of  baseline  pain  severity  on  improvement  in  functional  impairment  during
follow-up appeared to be moderated by treatment with duloxetine, but not by treatment with SSRIs.
4.1. Effects and Roles of Antidepressants in the Treatment of MDD in The Middle East
Treatment with antidepressants, both duloxetine and SSRIs, was found to be effective in improving functioning of
MDD patients in the Middle East. These findings are highly consistent with those of our previous studies with East
Asian patients,  which examined the effects  of  duloxetine with a  daily  dose of  ≤ 60mg and SSRIs,  respectively,  on
various clinical and humanistic outcomes [24, 26]. There are, however, no studies in the Middle East to have evaluated
the effects of antidepressants in the treatment of MDD, as confirmed in the recent systematic review by Travers et al.
[21]. This is rather surprising given the role of antidepressants in modern psychiatry and the high level of MDD burden
(in terms of DALYs) reported in this region [3, 4].
No regional  treatment  guidelines for  MDD are available  either,  except  for  the two published in a  neighbouring
country,  Turkey  [35,  37].  While  both  Turkish  and  other  international  guidelines  [38,  39]  recommend  the  use  of
antidepressants as first-line treatment of MDD, available evidence suggests that the rate of antidepressant use is low, but
that of benzodiazepine is relatively high in the treatment of MDD in the Middle East [21]. In our study, 21.1% and
20.0% of the MDD patients were reported to have taken benzodiazepines and antidepressants, respectively, in the 24
months prior to the study entry. The lack of regional clinical evidence might have contributed in part to the absence of
treatment guidelines and the lack of appropriate treatments for MDD in this region.
While our study found both duloxetine and SSRIs to be effective in improving functional impairment, duloxetine-
treated  patients  achieved  a  higher  level  of  functioning  than  SSRI-treated  patients  during  follow-up.  However,  the































152   Clinical Practice & Epidemiology in Mental Health, 2017, Volume 13 Hong et al.
limited evidence supports the advantage of SNRIs in subgroups of MDD patients with PPS and/or more severely ill [18,
41].  Notably,  the  majority  of  MDD Middle  Eastern  patients  in  this  study  exhibited  PPS  at  baseline  (63.8% in  the
duloxetine cohort and 58.5% in the SSRI cohort, p=0.371).
4.2. Implications of Depression-Related Pain in the Treatment of MDD in the Middle East
Our  study  also  found  differential  impacts  of  depression-related  pain  on  functioning  by  treatment  cohorts.
Duloxetine-treated patients achieved functioning independently of pain severity, but SSRI-related patients did not. That
is, SSRI-treated patients who had a higher level of depression-related pain at baseline did not achieve the same level of
functioning as those who had a lower level of depression-related pain at baseline, confirming the negative impact of
pain  on  improvement  in  functioning  in  this  cohort.  This  finding  adds  to  the  existing  evidence  that  supports  the
advantages of SNRIs in the subgroup of patients with PPS, as discussed above, and also reaffirms the importance of
pain control in the treatment of MDD.
Painful physical symptoms seemingly play dual roles in the treatment of MDD as both a trigger for help-seeking
and a risk factor for delayed diagnosis. Its dual role is particularly relevant in the Middle East, where mental illness
carries an intense and enduring stigma [42]. Patients in such cultures often tend to somatise their emotional problems
and  express  them in  terms  of  physical  symptoms.  This  may  partly  explain  the  high  percentage  of  painful  physical
symptoms (61.5% at baseline) found in our study, although it is not clear whether this is a manifestation of depressive
symptoms or a coexisting pain condition with an unknown aetiology.
Okasha reported that up to 80% of psychiatric patients have a tendency to somatise their emotional and psychiatric
problems [43]. Many of these patients therefore do not seek help in a psychiatric setting, but instead present to primary
care with physical complaints. This may explain the over-representation of depressed patients in primary care in the
Middle East.  Using the Beck Depression Inventory,  Hamdan et  al.  [12]  found that  nearly half  of  women attending
primary care clinics (n=224) in the UAE were mildly (14.3%), moderately (14.7%), or severely (17.9%) depressed (12).
Similarly, Becker et al. reported that about one in five patients attending primary care clinics (n=431) in Saudi Arabia
had depression and 67.4% of them were female, using the Patient Health Questionnaire (PHQ) [44]. The authors also
suggested  that  the  restrictive  Arab  culture  may  have  placed  women  at  higher  risk  for  somatic  presentations  of
psychological distress in primary care settings. This postulation is in line with the low proportion of women (34.6%)
included in our study, which was conducted in an outpatient psychiatric setting in the region. Becker further examined
whether there is a discrepancy in the detection rates of depression and somatisation between primary care physicians
and the  use  of  the  PHQ screening instrument  [45].  The study reported  that  primary care  physicians  were  aware  of
psychiatric disorders, but their diagnostic skills for these conditions were poor.
Taken  together,  a  substantial  proportion  of  MDD patients  in  the  Middle  East  also  suffer  from painful  physical
symptoms, which are likely to negatively impact on clinical outcomes, including functioning. Many of these patients
tend to seek help first from primary care physicians. It is therefore important to make sure that primary care physicians,
who are at the front-line of the healthcare system, correctly diagnose and treat MDD even in the presence of painful
physical symptoms.
4.3. Study Limitations
While  this  study  provides  meaningful  clinical  insights  into  MDD  in  the  Middle  East,  its  findings  should  be
interpreted  in  the  context  of  the  following  study  limitations.  Firstly,  data  were  taken  from an  observational  study.
Although the MMRM analysis adjusted for the baseline imbalance between duloxetine- and SSRI-treated patients, there
still exists the unobserved imbalance between the two cohorts. Secondly, the primary objective of the observational
study  was  to  assess  TESD in  the  treatment  of  MDD.  The  study,  therefore,  included  only  those  patients  who  were
sexually active and did not have sexual dysfunction at baseline. It has been reported that sexual dysfunction is two to
three  times  more  prevalent  in  patients  with  depression  than  in  the  general  population  [46,  47].  Our  findings  may
therefore not be immediately generalizable to MDD patients as a whole. In addition, sexual dysfunction was measured
using the Arizona Sexual Experience Scale [30]. It is not clear whether patients, especially women, were willing to
accurately report their sexual dysfunction, particularly in this restrictive culture. Further research is needed to examine
whether our findings can be replicated in MDD patients without such inclusion/exclusion criteria. Thirdly, even within
the SSRI class, there exist differences in efficacy and/or tolerability between the individual drugs [48]. Therefore, our
findings cannot represent the differences in effectiveness, in terms of functional improvement, between duloxetine and
any  specific  SSRIs.  Finally,  this  post-hoc  analysis  included  only  275  patients  from  the  Middle  East,  and  it  may
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therefore not be representative of all patients with MDD in the region. Our results should be interpreted with caution
until further replication is available.
CONCLUSION
Despite its limitations, this study provides some useful clinical insights into the treatment of MDD in the Middle
East. Patients treated with duloxetine achieved higher levels of functioning (i.e., global, work, social life, and family
life), compared to those treated with SSRIs for the management of MDD in actual clinical settings in the Middle East
(Saudi  Arabia  and  the  UAE).  The  study  also  revealed  a  high  proportion  of  MDD  patients  (61.5%)  suffering  from
painful physical symptoms, which was found to negatively impact on functioning. The negative impact of depression-
related pain was, however, moderated by treatment with duloxetine, but not by treatment with SSRIs. These findings
add to the existing but limited evidence that supports the additional advantage of duloxetine, and possibly SNRIs as a
whole, over SSRIs for the treatment of MDD patients presenting with painful physical symptoms. Given the high level
of  PPS  among  Middle  Eastern  MDD  patients,  it  is  particularly  important  to  make  sure  that  local  primary  care
physicians, who are at the front-line of the healthcare system, appropriately diagnose and treat MDD patients presenting
with physical complaints.
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